Dr. Ellis on Measuring Endocrine Therapy Efficacy

Matthew J. Ellis, MD, PhD, director, Section of Breast Oncology, Division of Oncology, Department of Medicine, Washington University, St Louis, MO, discusses determining the efficacy of endocrine therapy by measuring the Ki67 cell-proliferation marker after a few weeks of receiving therapy.

Ellis explains that endocrine therapy resistant ER-positive disease is the highest cause of deaths in breast cancer. By finding tumors that do not respond to endocrine therapy early on by using the Ki67 marker you can change therapies early in the treatment process.